CLAIMS AMENDMENTS

Please amend claims 1, and 66-150, as shown below. All other claims are unchanged.

1. (currently amended) A preparation for topically delivering and localizing at least one therapeutic agent~~s~~, comprising:

a vasoconstrictor for retarding vascular dispersion of a therapeutic agent, selected from the vasoconstrictor group consisting of at least one of: *phenylephrine, ephedrine sulfate, epinephrine, naphazoline,* and *oxymetazoline*; and

a penetration enhancer for facilitating penetration of said vasoconstrictor and said therapeutic agent through a patient's skin, selected from the penetration enhancer group consisting of at least one of: *lecithin* and *dimethylsulfoxide*; wherein:

said therapeutic agent is selected from ~~the therapeutic agent group consisting of~~ at least one ~~of~~therapeutic agent in at least one of the following therapeutic agent groups:

(a) a local anesthetic selected from the group consisting of: *bupivacaine, mepivacaine, levobupivacaine, ropivacaine, chloroprocaine, procaine, lidocaine, etidocaine, benzocaine, tetracaine,* and *prilocaine*;

(b) a quick-onset, short-acting non-steroidal anti-inflammatory agent selected from the group consisting of: *ketoprofen, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin,* and *tolmetin*;

(c) a long-acting non-steroidal anti-inflammatory agent selected from the group consisting of: *piroxicam, celecoxib, meloxicam, nabumetone, naproxen, oxaprozin, rofecoxib, sulindac,* and *valdecoxib*; ~~and~~

(d) an antiviral agent selected from the group consisting of: *2-deoxy-d-glucose, podofilox, acyclovir, penciclovir,* and *docosanol*.

2. (withdrawn, original) The preparation of claim 1, said vasoconstrictor comprising *phenylephrine*.

3. (withdrawn, original) The preparation of claim 2, wherein:

a clinical concentration of said *phenylephrine* is at least approximately 0.125%; and

said clinical concentration of said *phenylephrine* is at most approximately 1.0%.

4. (withdrawn, original) The preparation of claim 3, wherein said clinical concentration of said *phenylephrine* is approximately 0.5%.

5. (withdrawn, original) The preparation of claim 1, said vasoconstrictor comprising a vasoconstrictor selected from the vasoconstrictor group consisting of: *ephedrine sulfate, epinephrine, naphazoline,* and *oxymetazoline*.

6. (withdrawn, original) The preparation of claim 1, said penetration enhancer comprising *dimethylsulfoxide*.

7. (withdrawn, original) The preparation of claim 6, wherein

a clinical concentration of said *dimethylsulfoxide* is at most approximately 10%.

8. (withdrawn, original) The preparation of claim 7, wherein said clinical concentration of said *dimethylsulfoxide* is approximately 10%.

9. (withdrawn, original) The preparation of claim 1, said penetration enhancer comprising *lecithin*.

10. (withdrawn, original) The preparation of claim 9, said penetration enhancer further comprising *ethoxy diglycol*.

11. (withdrawn, original) The preparation of claim 9, wherein:

a clinical concentration of said *lecithin* is at least approximately 2%; and

said clinical concentration of said *lecithin* is at most approximately 50%.

12. (withdrawn, original) The preparation of claim 11, wherein:

said clinical concentration of said *lecithin* is approximately 10% to 12%.

13. (withdrawn, original) The preparation of claim 1:

said vasoconstrictor comprising *phenylephrine*; and

said penetration enhancer comprising *dimethylsulfoxide*.

14. (withdrawn, original) The preparation of claim 13, wherein:

a clinical concentration of said *phenylephrine* is at least

approximately 0.125%;

said clinical concentration of said *phenylephrine* is at most approximately 1.0%; and

a clinical concentration of said *dimethylsulfoxide* is at most approximately 10%.

15. (withdrawn, original) The preparation of claim 14, wherein:

said clinical concentration of said *phenylephrine* is approximately 0.5%; and

said clinical concentration of said *dimethylsulfoxide* is approximately 10%.

16. (withdrawn, original) The preparation of claim 13, wherein:

a ratio of a clinical concentration of said *dimethylsulfoxide* to a clinical concentration of said *phenylephrine* is at most approximately 40 to 1.

17. (withdrawn, original) The preparation of claim 1:

said vasoconstrictor comprising *phenylephrine*; and

said penetration enhancer comprising *lecithin*.

18. (withdrawn, original) The preparation of claim 17, said penetration enhancer further comprising *ethoxy diglycol*.

19. (withdrawn, original) The preparation of claim 17, wherein:

a clinical concentration of said *phenylephrine* is at least

approximately 0.125%;

said clinical concentration of said *phenylephrine* is at most approximately 1.0%; and

a clinical concentration of said *lecithin* is at most approximately 50%.

20. (withdrawn, original) The preparation of claim 19, wherein:

said clinical concentration of said *phenylephrine* is approximately 0.5%; and

said clinical concentration of said *lecithin* is approximately 10% to 12%.

21. (withdrawn, original) The preparation of claim 17, wherein:

a ratio of a clinical concentration of said *lecithin* to a clinical concentration of said *phenylephrine* is at most approximately 200 to 1.

22. (withdrawn, original) The preparation of claim 1, further comprising:

said therapeutic agent.

23. (withdrawn, original) The preparation of claim 22, particularly for relieving pain, comprising:

said therapeutic agent comprising a therapeutic pain-relieving agent;

said penetration enhancer for facilitating penetration of

said therapeutic pain-relieving agent and said vasoconstrictor through the patient's skin; and

said vasoconstrictor for retarding vascular dispersion of said therapeutic agent.

24. (withdrawn, original) The preparation of claim 23, said therapeutic pain-relieving agent comprising:

a local anesthetic.

25. (withdrawn, original) The preparation of claim 24, said local anesthetic comprising *bupivacaine*.

26. (withdrawn, original) The preparation of claim 25, wherein:

a clinical concentration of said *bupivacaine* is at least approximately 2%; and

said clinical concentration of said *bupivacaine* is at most approximately 10%.

27. (withdrawn, original) The preparation of claim 26, wherein said clinical concentration of said *bupivacaine* is approximately 5%.

28. (withdrawn, original) The preparation of claim 24, said local anesthetic comprising a local anesthetic selected from the local anesthetic group consisting of: *mepivacaine*, *levobupivacaine*, *ropivacaine*, *chloroprocaine*, *procaine*, *lidocaine*, *etidocaine*, *benzocaine*, *tetracaine*, and *prilocaine*.

29. (withdrawn, original) The preparation of claim 23, said

therapeutic pain-relieving agent comprising:

a quick-onset, short-acting non-steroidal anti-inflammatory agent.

30. (withdrawn, original) The preparation of claim 29, said quick-onset, short-acting non-steroidal anti-inflammatory agent comprising *ketoprofen*.

31. (withdrawn, original) The preparation of claim 30, wherein:

a clinical concentration of said *ketoprofen* is at least approximately 5%; and

said clinical concentration of said *ketoprofen* is at most approximately 20%.

32. (withdrawn, original) The preparation of claim 31, wherein said clinical concentration of said *ketoprofen* is approximately 10%.

33. (withdrawn, original) The preparation of claim 29, said quick-onset, short-acting non-steroidal anti-inflammatory agent comprising a quick-onset, short-acting non-steroidal anti-inflammatory agent selected from the quick-onset, short-acting non-steroidal anti-inflammatory agent group consisting of: *diclofenac*, *diflunisal*, *etodolac*, *fenoprofen*, *flurbiprofen*, *ibuprofen*, *indomethacin*, and *tolmetin*.

34. (withdrawn, original) The preparation of claim 23, said therapeutic pain-relieving agent comprising:

a long-acting non-steroidal anti-inflammatory agent.

35. (withdrawn, original) The preparation of claim 34, said long-acting non-steroidal anti-inflammatory agent comprising *piroxicam*.

36. (withdrawn, original) The preparation of claim 35, wherein:

a clinical concentration of said *piroxicam* is at least approximately 0.5%; and

said clinical concentration of said *piroxicam* is at most approximately 4%.

37. (withdrawn, original) The preparation of claim 36, wherein said clinical concentration of said *piroxicam* is approximately 1.0%.

38. (withdrawn, original) The preparation of claim 34, said long-acting non-steroidal anti-inflammatory agent comprising a long-acting non-steroidal anti-inflammatory agent selected from the long-acting non-steroidal anti-inflammatory agent group consisting of: *celecoxib*, *meloxicam*, *nabumetone*, *naproxen*, *oxaprozin*, *rofecoxib*, *sulindac*, and *valdecoxib*.

39. (withdrawn, original) The preparation of claim 23, said therapeutic pain-relieving agent comprising:

a local anesthetic; and

a quick-onset, short-acting non-steroidal anti-inflammatory agent.

40. (withdrawn, original) The preparation of claim 39:

said local anesthetic comprising *bupivacaine*; and

said quick-onset, short-acting non-steroidal anti-inflammatory agent comprising *ketoprofen*.

41. (withdrawn, original) The preparation of claim 23, said therapeutic pain-relieving agent comprising:

a local anesthetic; and

a long-acting non-steroidal anti-inflammatory agent.

42. (withdrawn, original) The preparation of claim 41:

said local anesthetic comprising *bupivacaine*; and

said long-acting non-steroidal anti-inflammatory agent comprising *piroxicam*.

43. (withdrawn, original) The preparation of claim 23, said therapeutic pain-relieving agent comprising:

a quick-onset, short-acting non-steroidal anti-inflammatory agent; and

a long-acting non-steroidal anti-inflammatory agent.

44. (withdrawn, original) The preparation of claim 43:

said quick-onset, short-acting non-steroidal anti-inflammatory agent comprising *ketoprofen*; and

said long-acting non-steroidal anti-inflammatory agent comprising *piroxicam*.

45. (withdrawn, original) The preparation of claim 23, said therapeutic pain-relieving agent comprising:

a local anesthetic;

a quick-onset, short-acting non-steroidal anti-inflammatory agent; and

a long-acting non-steroidal anti-inflammatory agent.

46. (withdrawn, original) The preparation of claim 45:

said local anesthetic comprising *bupivacaine*;

said quick-onset, short-acting non-steroidal anti-inflammatory agent comprising *ketoprofen*; and

said long-acting non-steroidal anti-inflammatory agent comprising *piroxicam*.

47. (withdrawn, original) The preparation of claim 46, wherein:

a clinical concentration of said *bupivacaine* is at least approximately 2%;

said clinical concentration of said *bupivacaine* is at most approximately 10%;

a clinical concentration of said *ketoprofen* is at least approximately 5%;

said clinical concentration of said *ketoprofen* is at most approximately 20%;

a clinical concentration of said *piroxicam* is at least approximately 0.5%; and

said clinical concentration of said *piroxicam* is at most approximately 4%.

48. (withdrawn, original) The preparation of claim 47, wherein:

said clinical concentration of said *bupivacaine* is approximately 5%;

said clinical concentration of said *ketoprofen* is approximately 10%; and

said clinical concentration of said *piroxicam* is approximately 1.0%

49. (withdrawn, original) The preparation of claim 22, particularly for treating a viral disease, comprising:

said therapeutic agent comprising an antiviral agent;

said penetration enhancer for facilitating penetration of said antiviral agent and said vasoconstrictor through the patient's skin; and

said vasoconstrictor for retarding vascular dispersion of said antiviral agent.

50. (withdrawn, original) The preparation of claim 49, said antiviral agent comprising *2-deoxy-d-glucose*.

51. (withdrawn, original) The preparation of claim 50, wherein:

a clinical concentration of said *2-deoxy-d-glucose* is at least approximately 0.1%; and

said clinical concentration of said *2-deoxy-d-glucose* is at most approximately 0.4%.

52. (withdrawn, original) The preparation of claim 51, wherein:

said clinical concentration of said *2-deoxy-d-glucose* is approximately 0.2%.

53. (withdrawn, original) The preparation of claim 49, said antiviral agent comprising an antiviral agent selected from the antiviral agent group consisting of: *podofilox*, *acyclovir*, *penciclovir*, and *docosanol*.

54. (withdrawn, original) The preparation of claim 23, particularly for relieving pain from a viral disease and treating the viral disease, comprising:

said therapeutic agent further comprising an antiviral agent;

said penetration enhancer for further facilitating penetration of said antiviral agent through the patient's skin; and

said vasoconstrictor for further retarding vascular dispersion of said antiviral agent.

55. (withdrawn, original) The preparation of claim 54, said antiviral agent comprising *2-deoxy-d-glucose*.

56. (withdrawn, original) The preparation of claim 55, wherein:

a clinical concentration of said *2-deoxy-d-glucose* is at least approximately 0.1%; and

said clinical concentration of said *2-deoxy-d-glucose* is at most approximately 0.4%.

57. (withdrawn, original) The preparation of claim 56, wherein:

said clinical concentration of said *2-deoxy-d-glucose* is approximately 0.2%.

58. (withdrawn, original) The preparation of claim 54, said antiviral agent comprising an antiviral agent selected from the antiviral agent group consisting of: *podofilox*, *acyclovir*, *penciclovir*, and *docosanol*.

59. (withdrawn, original) The preparation of claim 45:

said vasoconstrictor comprising *phenylephrine*;

said penetration enhancer comprising a penetration enhancing agent selected from the penetration-enhancing agent group consisting of *dimethylsulfoxide* and *lecithin*;

said local anesthetic comprising *bupivacaine*;

said quick-onset, short-acting non-steroidal anti-inflammatory agent comprising *ketoprofen*; and

said long-acting non-steroidal anti-inflammatory agent comprising *piroxicam*.

60. (withdrawn, original) The preparation of claim 59, wherein:

a clinical concentration of said *phenylephrine* is at least approximately 0.125%;

said clinical concentration of said *phenylephrine* is at most approximately 1.0%;

a clinical concentration of said *dimethylsulfoxide* is at most approximately 10%;

a clinical concentration of said *lecithin* is at most approximately 50%;

a clinical concentration of said *bupivacaine* is at least approximately 2%;

said clinical concentration of said *bupivacaine* is at most approximately 10%;

a clinical concentration of said *ketoprofen* is at least approximately 5%;

said clinical concentration of said *ketoprofen* is at most approximately 20%;

a clinical concentration of said *piroxicam* is at least approximately 0.5%; and

said clinical concentration of said *piroxicam* is at most approximately 4%.

61. (withdrawn, original) The preparation of claim 60, wherein:

said clinical concentration of said *phenylephrine* is approximately 0.5%;

said clinical concentration of said *bupivacaine* is approximately 5%;

said clinical concentration of said *ketoprofen* is approximately 10%; and

said clinical concentration of said *piroxicam* is approximately 1.0%.

62. (withdrawn, original) The preparation of claim 45, additionally for treating a viral disease, said therapeutic agent further comprising:

an antiviral agent.

63. (withdrawn, original) The preparation of claim 62:

said vasoconstrictor comprising *phenylephrine*;

said penetration enhancer comprising a penetration enhancing agent selected from the penetration-enhancing agent group consisting of *dimethylsulfoxide* and *lecithin*;

said local anesthetic comprising *bupivacaine*;

said quick-onset, short-acting non-steroidal anti-inflammatory agent comprising *ketoprofen*;

said long-acting non-steroidal anti-inflammatory agent comprising *piroxicam*; and

said antiviral agent comprising *2-deoxy-d-glucose*.

64. (withdrawn, original) The preparation of claim 63, wherein:

a clinical concentration of said *phenylephrine* is at least approximately 0.125%;

said clinical concentration of said *phenylephrine* is at

most approximately 1.0%;

a clinical concentration of said *dimethylsulfoxide* is at most approximately 10%;

a clinical concentration of said *lecithin* is at most approximately 50%;

a clinical concentration of said *bupivacaine* is at least approximately 2%;

said clinical concentration of said *bupivacaine* is at most approximately 10%;

a clinical concentration of said *ketoprofen* is at least approximately 5%;

said clinical concentration of said *ketoprofen* is at most approximately 20%;

a clinical concentration of said *piroxicam* is at least approximately 0.5%;

said clinical concentration of said *piroxicam* is at most approximately 4%;

a clinical concentration of said *2-deoxy-d-glucose* is at least approximately 0.1%; and

said clinical concentration of said *2-deoxy-d-glucose* is at most approximately 0.4%.

65. (withdrawn, original) The preparation of claim 64, wherein:

said clinical concentration of said *phenylephrine* is

approximately 0.5%;

said clinical concentration of said *bupivacaine* is approximately 5%;

said clinical concentration of said *ketoprofen* is approximately 10%;

said clinical concentration of said *piroxicam* is approximately 1.0%; and

said clinical concentration of said *2-deoxy-d-glucose* is approximately 0.2%.

66. (withdrawn, currently amended) A method of topically delivering and localizing at least one therapeutic agent~~s~~, comprising:

using a vasoconstrictor for retarding vascular dispersion of a therapeutic agent, selected from the vasoconstrictor group consisting of at least one of: *phenylephrine, ephedrine sulfate, epinephrine*, *naphazoline*, and *oxymetazoline*; in combination with

using a penetration enhancer for facilitating penetration of said vasoconstrictor and said therapeutic agent through a patient's skin, selected from the penetration enhancer group consisting of at least one of: *lecithin* and *dimethylsulfoxide*; wherein:

said therapeutic agent is selected from ~~the therapeutic agent group consisting of~~ at least one ~~of~~therapeutic agent in at least one of the following therapeutic agent groups:

(a) a local anesthetic selected from the group consisting of: *bupivacaine*, *mepivacaine*, *levobupivacaine*, *ropivacaine*, *chloroprocaine*, *procaine*, *lidocaine*, *etidocaine*, *benzocaine*, *tetracaine*, and *prilocaine*;

(b) a quick-onset, short-acting non-steroidal anti-inflammatory agent selected from the group consisting of: *ketoprofen*, *diclofenac*, *diflunisal*, *etodolac*, *fenoprofen*, *flurbiprofen*, *ibuprofen*, *indomethacin*, and *tolmetin*;

(c) a long-acting non-steroidal anti-inflammatory agent selected from the group consisting of: *piroxicam*, *celecoxib*, *meloxicam*, *nabumetone*, *naproxen*, *oxaprozin*, *rofecoxib*, *sulindac*, and *valdecoxib*; ~~and~~

(d) an antiviral agent selected from the group consisting of: *2-deoxy-d-glucose*, *podofilox*, *acyclovir*, *penciclovir*, and *docosanol*.

67. (withdrawn, currently amended) The method of claim 66 , said ~~step of~~ using said vasoconstrictor further comprising ~~the step of~~ using *phenylephrine*.

68. (withdrawn, currently amended) The method of claim 67, further comprising ~~the steps of~~:

using a clinical concentration of said *phenylephrine*, of at least approximately 0.125%; and

using said clinical concentration of said *phenylephrine*, of at most approximately 1.0%.

69. (withdrawn, currently amended) The method of claim 68, further comprising ~~the step of~~ using said clinical concentration of said *phenylephrine*, of approximately 0.5%.

70. (withdrawn, currently amended) The method of claim 66 , said ~~step of~~ using said vasoconstrictor further comprising ~~the step of~~ using a vasoconstrictor selected from the vasoconstrictor group consisting of: *ephedrine sulfate*, *epinephrine*, *naphazoline*, and *oxymetazoline*.

71. (withdrawn, currently amended) The method of claim 66, said ~~step of~~ using said penetration enhancer further comprising ~~the step of~~ using *dimethylsulfoxide*.

72. (withdrawn, currently amended) The method of claim 71, further comprising ~~the step of~~ using a clinical concentration of said *dimethylsulfoxide*, of at most approximately 10%.

73. (withdrawn, currently amended) The method of claim 72, further comprising ~~the step of~~ using said clinical concentration of said *dimethylsulfoxide*, of approximately 10%.

74. (withdrawn, currently amended) The method of claim 66, said ~~step of~~ using said penetration enhancer further comprising ~~the step of~~ using comprising *lecithin*.

75. (withdrawn, currently amended) The method of claim 74, said ~~step of~~ using said penetration enhancer further comprising ~~the step of~~ using *ethoxy diglycol*.

76. (withdrawn, currently amended) The method of claim 74,

further comprising ~~the steps of~~:

using a clinical concentration of said *lecithin*, of at least approximately 2%; and

using said clinical concentration of said *lecithin*, of at most approximately 50%.

77. (withdrawn, currently amended) The method of claim 76, further comprising ~~the step of~~:

using said clinical concentration of said *lecithin*, of approximately 10% to 12%.

78. (withdrawn, currently amended) The method of claim 66:

said ~~step of~~ using said vasoconstrictor further comprising ~~the step of~~ using *phenylephrine*; and

said ~~step of~~ using said penetration enhancer further comprising ~~the step of~~ using *dimethylsulfoxide*.

79. (withdrawn, currently amended) The method of claim 78, further comprising ~~the steps of~~:

using a clinical concentration of said *phenylephrine*, of at least approximately 0.125%;

using said clinical concentration of said *phenylephrine*, of at most approximately 1.0%; and

using a clinical concentration of said *dimethylsulfoxide*, of at most approximately 10%.

80. (withdrawn, currently amended) The method of claim 79, further comprising ~~the steps of~~:

using said clinical concentration of said *phenylephrine*, of approximately 0.5%; and

using said clinical concentration of said *dimethylsulfoxide*, of approximately 10%.

81. (withdrawn, currently amended) The method of claim 78, further comprising ~~the step of~~:

using a ratio of a clinical concentration of said *dimethylsulfoxide* to a clinical concentration of said *phenylephrine*, of at most approximately 40 to 1.

82. (withdrawn, currently amended) The method of claim 66:

said ~~step of~~ using said vasoconstrictor further comprising ~~the step of~~ using *phenylephrine*; and

said ~~step of~~ using said penetration enhancer further comprising ~~the step of~~ using *lecithin*.

83. (withdrawn, currently amended) The method of claim 82, said ~~step of~~ using said penetration enhancer further comprising ~~the step of~~ using *ethoxy diglycol*.

84. (withdrawn, currently amended) The method of claim 82, further comprising ~~the steps of~~:

using a clinical concentration of said *phenylephrine*, of at least approximately 0.125%;

using said clinical concentration of said *phenylephrine*, of at most approximately 1.0%; and

using a clinical concentration of said *lecithin*, of at most

approximately 50%.

85. (withdrawn, currently amended) The method of claim 84, further comprising ~~the steps of~~:

using said clinical concentration of said *phenylephrine*, of approximately 0.5%; and

using said clinical concentration of said *lecithin*, of approximately 10% to 12%.

86. (withdrawn, currently amended) The method of claim 82, further comprising ~~the step of~~:

using a ratio of a clinical concentration of said *lecithin* to a clinical concentration of said *phenylephrine*, of at most approximately 200 to 1.

87. (withdrawn, currently amended) The method of claim 66, further comprising ~~the step of~~:

using said therapeutic agent in combination with using said vasoconstrictor and using said penetration enhancer.

88. (withdrawn, currently amended) The method of claim 87, particularly for relieving pain:

said ~~step of~~ using said therapeutic agent further comprising ~~the step of~~ using a therapeutic pain-relieving agent; further comprising ~~the steps of~~:

using said penetration enhancer for facilitating penetration of said therapeutic pain-relieving agent and said vasoconstrictor through the patient's skin; and

using said vasoconstrictor for retarding vascular dispersion of said therapeutic agent.

89. (withdrawn, currently amended) The method of claim 88, said ~~step of~~ using said therapeutic pain-relieving agent further comprising ~~the step of~~ using a local anesthetic.

90. (withdrawn, currently amended) The method of claim 89, said ~~step of~~ using said local anesthetic further comprising ~~the step of~~ using *bupivacaine*.

91. (withdrawn, currently amended) The method of claim 90, further comprising ~~the steps of~~:

using a clinical concentration of said *bupivacaine*, of at least approximately 2%; and

using said clinical concentration of said *bupivacaine*, of at most approximately 10%.

92. (withdrawn, currently amended) The method of claim 91, further comprising ~~the step of~~ using said clinical concentration of said *bupivacaine*, of approximately 5%.

93. (withdrawn, currently amended) The method of claim 89, said ~~step of~~ using said local anesthetic further comprising ~~the step of~~ using a local anesthetic selected from the local anesthetic group consisting of: *mepivacaine*, *levobupivacaine*, *ropivacaine*, *chloroprocaine*, *procaine*, *lidocaine*, *etidocaine*, *benzocaine*, *tetracaine*, and *prilocaine*.

94. (withdrawn, currently amended) The method of claim 88,

said ~~step of~~ using said therapeutic pain-relieving agent further comprising ~~the step of~~ using a quick-onset, short-acting non-steroidal anti-inflammatory agent.

95. (withdrawn, currently amended) The method of claim 94, said ~~step of~~ using said quick-onset, short-acting non-steroidal anti-inflammatory agent further comprising ~~the step of~~ using *ketoprofen*.

96. (withdrawn, currently amended) The method of claim 95, further comprising ~~the step of~~:

using a clinical concentration of said *ketoprofen*, of at least approximately 5%; and

said clinical concentration of said *ketoprofen*, of at most approximately 20%.

97. (withdrawn, currently amended) The method of claim 96, further comprising ~~the step of~~ using said clinical concentration of said *ketoprofen*, of approximately 10%.

98. (withdrawn, currently amended) The method of claim 94, said ~~step of~~ using said quick-onset, short-acting non-steroidal anti-inflammatory agent further comprising ~~the step of~~ using a quick-onset, short-acting non-steroidal anti-inflammatory agent selected from the quick-onset, short-acting non-steroidal anti-inflammatory agent group consisting of: *diclofenac*, *diflunisal*, *etodolac*, *fenoprofen*, *flurbiprofen*, *ibuprofen*, *indomethacin*, and *tolmetin*.

99. (withdrawn, currently amended) The method of claim 88, said ~~step of~~ using said therapeutic pain-relieving agent further comprising ~~the step of~~ using a long-acting non-steroidal anti-inflammatory agent.

100. (withdrawn, currently amended) The method of claim 99, said ~~step of~~ using said long-acting non-steroidal anti-inflammatory agent further comprising ~~the step of~~ using *piroxicam*.

101. (withdrawn, currently amended) The method of claim 100, further comprising ~~the steps of~~:

using a clinical concentration of said *piroxicam*, of at least approximately 0.5%; and

using said clinical concentration of said *piroxicam*, of at most approximately 4%.

102. (withdrawn, currently amended) The method of claim 101, further comprising ~~the step of~~ using said clinical concentration of said *piroxicam*, of approximately 1.0%.

103. (withdrawn, currently amended) The method of claim 99, said ~~step of~~ using said long-acting non-steroidal anti-inflammatory agent further comprising ~~the step of~~ using a long-acting non-steroidal anti-inflammatory agent selected from the long-acting non-steroidal anti-inflammatory agent group consisting of: *celecoxib*, *meloxicam*, *nabumetone*, *naproxen*, *oxaprozin*, *rofecoxib*, *sulindac*, and *valdecoxib*.

104. (withdrawn, currently amended) The method of claim 88, said ~~step of~~ using said therapeutic pain-relieving agent further comprising ~~the steps of~~:

using a local anesthetic; and

using a quick-onset, short-acting non-steroidal anti-inflammatory agent.

105. (withdrawn, currently amended) The method of claim 104:

said ~~step of~~ using said local anesthetic further comprising ~~the step of~~ using *bupivacaine*; and

said ~~step of~~ using said quick-onset, short-acting non-steroidal anti-inflammatory agent further comprising ~~the step of~~ using *ketoprofen*.

106. (withdrawn, currently amended) The method of claim 88, said ~~step of~~ using said therapeutic pain-relieving agent further comprising ~~the steps of~~::

using a local anesthetic; and

using a long-acting non-steroidal anti-inflammatory agent.

107. (withdrawn, currently amended) The method of claim 106:

said ~~step of~~ using said local anesthetic further comprising ~~the step of~~ using *bupivacaine*; and

said ~~step of~~ using said long-acting non-steroidal anti-inflammatory agent further comprising ~~the step of~~ using *piroxicam*.

108. (withdrawn, currently amended) The method of claim 88,

said ~~step of~~ using said therapeutic pain-relieving agent further comprising ~~the steps of~~::

using a quick-onset, short-acting non-steroidal anti-inflammatory agent; and

using a long-acting non-steroidal anti-inflammatory agent.

109. (withdrawn, currently amended) The method of claim 108:

said ~~step of~~ using said quick-onset, short-acting non-steroidal anti-inflammatory agent further comprising ~~the step of~~ using *ketoprofen*; and

said ~~step of~~ using said long-acting non-steroidal anti-inflammatory agent further comprising ~~the step of~~ using *piroxicam*.

110. (withdrawn, currently amended) The method of claim 88, said ~~step of~~ using said therapeutic pain-relieving agent further comprising ~~the steps of~~:

using a local anesthetic;

using a quick-onset, short-acting non-steroidal anti-inflammatory agent; and

using a long-acting non-steroidal anti-inflammatory agent.

111. (withdrawn, currently amended) The method of claim 110:

said ~~step of~~ using said local anesthetic further comprising ~~the step of~~ using *bupivacaine*;

said ~~step of~~ using said quick-onset, short-acting non-steroidal anti-inflammatory agent further comprising ~~the step of~~

using *ketoprofen*; and

said ~~step of~~ using said long-acting non-steroidal anti-inflammatory agent further comprising ~~the step of~~ using *piroxicam*.

112. (withdrawn, currently amended) The method of claim 111, further comprising ~~the steps of~~:

using a clinical concentration of said *bupivacaine*, of at least approximately 2%;

using said clinical concentration of said *bupivacaine*, of at most approximately 10%;

using a clinical concentration of said *ketoprofen*, of at least approximately 5%;

using said clinical concentration of said *ketoprofen*, of at most approximately 20%;

using a clinical concentration of said *piroxicam*, of at least approximately 0.5%; and

using said clinical concentration of said *piroxicam*, of at most approximately 4%.

113. (withdrawn, currently amended) The method of claim 112, further comprising ~~the steps of~~:

using said clinical concentration of said *bupivacaine*, of approximately 5%;

using said clinical concentration of said *ketoprofen*, of approximately 10%; and

using said clinical concentration of said *piroxicam*, of approximately 1.0%.

114. (withdrawn, currently amended) The method of claim 87, particularly for treating a viral disease:

said ~~step of~~ using said therapeutic agent further comprising ~~the step of~~ using an antiviral agent; further comprising ~~the steps of~~:

using said penetration enhancer for facilitating penetration of said antiviral agent and said vasoconstrictor through the patient's skin; and

using said vasoconstrictor for retarding vascular dispersion of said antiviral agent.

115. (withdrawn, currently amended) The method of claim 114, said ~~step of~~ using said antiviral agent further comprising ~~the step of~~ using *2-deoxy-d-glucose*.

116. (withdrawn, currently amended) The method of claim 115, further comprising ~~the steps of~~:

using a clinical concentration of said *2-deoxy-d-glucose*, of at least approximately 0.1%; and

using said clinical concentration of said *2-deoxy-d-glucose*, of at most approximately 0.4%.

117. (withdrawn, currently amended) The method of claim 116, further comprising ~~the step of~~:

using said clinical concentration of said *2-deoxy-d-*

glucose, of approximately 0.2%.

118. (withdrawn, currently amended) The method of claim 114, said ~~step of~~ using said antiviral agent further comprising ~~the step of~~ using an antiviral agent selected from the antiviral agent group consisting of: *podofilox*, *acyclovir*, *penciclovir*, and *docosanol*.

119. (withdrawn, currently amended) The method of claim 88, particularly for relieving pain from a viral disease and treating the viral disease:

said ~~step of~~ using said therapeutic agent further comprising ~~the step of~~ using an antiviral agent; further comprising ~~the steps of~~:

using said penetration enhancer for further facilitating penetration of said antiviral agent through the patient's skin; and

using said vasoconstrictor for further retarding vascular dispersion of said antiviral agent.

120. (withdrawn, currently amended) The method of claim 119, said ~~step of~~ using said antiviral agent further comprising ~~the step of~~ using *2-deoxy-d-glucose*.

121. (withdrawn, currently amended) The method of claim 120, further comprising ~~the steps of~~:

using a clinical concentration of said *2-deoxy-d-glucose*, of at least approximately 0.1%; and

using said clinical concentration of said *2-deoxy-d-glucose*, of at most approximately 0.4%.

122. (withdrawn, currently amended) The method of claim 121, further comprising ~~the step of~~:

using said clinical concentration of said *2-deoxy-d-glucose*, of approximately 0.2%.

123. (withdrawn, currently amended) The method of claim 119, said ~~step of~~ using said antiviral agent further comprising ~~the step of~~ using an antiviral agent selected from the antiviral agent group consisting of: *podofilox*, *acyclovir*, *penciclovir*, and *docosanol*.

124. (withdrawn, currently amended) The method of claim 110:

said ~~step of~~ using said vasoconstrictor further comprising ~~the step of~~ using *phenylephrine*;

said ~~step of~~ using said penetration enhancer further comprising ~~the step of~~ using a penetration enhancing agent selected from the penetration-enhancing agent group consisting of *dimethylsulfoxide* and *lecithin*;

said ~~step of~~ using said local anesthetic further comprising ~~the step of~~ using *bupivacaine*;

said ~~step of~~ using said quick-onset, short-acting non-steroidal anti-inflammatory agent further comprising ~~the step of~~ using *ketoprofen*; and

said ~~step of~~ using said long-acting non-steroidal anti-

inflammatory agent further comprising ~~the step of~~ using *piroxicam*.

125. (withdrawn, currently amended) The method of claim 124, further comprising ~~the steps of~~:

using a clinical concentration of said *phenylephrine*, of at least approximately 0.125%;

using said clinical concentration of said *phenylephrine*, of at most approximately 1.0%;

using a clinical concentration of said *dimethylsulfoxide*, of at most approximately 10%;

using a clinical concentration of said *lecithin*, of at most approximately 50%;

using a clinical concentration of said *bupivacaine*, of at least approximately 2%;

using said clinical concentration of said *bupivacaine*, of at most approximately 10%;

using a clinical concentration of said *ketoprofen*, of at least approximately 5%;

using said clinical concentration of said *ketoprofen*, of at most approximately 20%;

using a clinical concentration of said *piroxicam*, of at least approximately 0.5%; and

using said clinical concentration of said *piroxicam*, of at most approximately 4%.

126. (withdrawn, currently amended) The method of claim 125, further comprising ~~the steps of~~:

using said clinical concentration of said *phenylephrine*, of approximately 0.5%;

using said clinical concentration of said *bupivacaine*, of approximately 5%;

using said clinical concentration of said *ketoprofen*, of approximately 10%; and

using said clinical concentration of said *piroxicam*, of approximately 1.0%.

127. (withdrawn, currently amended) The method of claim 110, additionally for treating a viral disease, said ~~step of~~ using said therapeutic agent further comprising ~~the step of~~ using an antiviral agent.

128. (withdrawn, currently amended) The method of claim 127:

said ~~step of~~ using said vasoconstrictor further comprising ~~the step of~~ using *phenylephrine*;

said ~~step of~~ using said penetration enhancer further comprising ~~the step of~~ using a penetration enhancing agent selected from the penetration-enhancing agent group consisting of *dimethylsulfoxide* and *lecithin*;

said ~~step of~~ using said local anesthetic further comprising ~~the step of~~ using *bupivacaine*;

said ~~step of~~ using said quick-onset, short-acting non-

steroidal anti-inflammatory agent further comprising ~~the step of~~ using *ketoprofen*;

said ~~step of~~ using said long-acting non-steroidal anti-inflammatory agent further comprising ~~the step of~~ using *piroxicam*; and

said ~~step of~~ using said antiviral agent further comprising ~~the step of~~ using *2-deoxy-d-glucose*.

129. (withdrawn, currently amended) The method of claim 128, further comprising ~~the steps of~~:

using a clinical concentration of said *phenylephrine*, of at least approximately 0.125%;

using said clinical concentration of said *phenylephrine*, of at most approximately 1.0%;

using a clinical concentration of said *dimethylsulfoxide*, of at most approximately 10%;

using a clinical concentration of said *lecithin*, of at most approximately 50%;

using a clinical concentration of said *bupivacaine*, of at least approximately 2%;

using said clinical concentration of said *bupivacaine*, of at most approximately 10%;

using a clinical concentration of said *ketoprofen*, of at least approximately 5%;

using said clinical concentration of said *ketoprofen*, of at

most approximately 20%;

using a clinical concentration of said *piroxicam*, of at least approximately 0.5%;

using said clinical concentration of said *piroxicam*, of at most approximately 4%;

using a clinical concentration of said *2-deoxy-d-glucose*, of at least approximately 0.1%; and

using said clinical concentration of said *2-deoxy-d-glucose*, of at most approximately 0.4%.

130. (withdrawn, currently amended) The method of claim 129, further comprising ~~the steps of~~:

using said clinical concentration of said *phenylephrine*, of approximately 0.5%;

using said clinical concentration of said *bupivacaine*, of approximately 5%;

using said clinical concentration of said *ketoprofen*, of approximately 10%;

using said clinical concentration of said *piroxicam*, of approximately 1.0%; and

using said clinical concentration of said *2-deoxy-d-glucose*, of approximately 0.2%.

131. (withdrawn, currently amended) The method of claim 66, further comprising ~~the step of~~:

applying said vasoconstrictor and said penetration enhancer

to the patient's skin.

132. (withdrawn, currently amended) The method of claim 78, further comprising ~~the step of~~:

applying said *phenylephrine* and said *dimethylsulfoxide* to the patient's skin.

133. (withdrawn, currently amended) The method of claim 82, further comprising ~~the step of~~:

applying said *phenylephrine* and said *lecithin* to the patient's skin.

134. (withdrawn, currently amended) The method of claim 87, further comprising ~~the step of~~:

applying said vasoconstrictor, said penetration enhancer, and said therapeutic agent to the patient's skin.

135. (withdrawn, currently amended) The method of claim 88, further comprising ~~the step of~~:

applying said vasoconstrictor, said penetration enhancer, and said therapeutic pain-relieving agent to the patient's skin.

136. (withdrawn, currently amended) The method of claim 89, further comprising ~~the step of~~:

applying said vasoconstrictor, said penetration enhancer, and said local anesthetic to the patient's skin.

137. (withdrawn, currently amended) The method of claim 90, further comprising ~~the step of~~:

applying said vasoconstrictor, said penetration enhancer,

and said *bupivacaine* to the patient's skin.

138. (withdrawn, currently amended) The method of claim 94, further comprising ~~the step of~~:

applying said vasoconstrictor, said penetration enhancer, and said quick-onset, short-acting non-steroidal anti-inflammatory agent to the patient's skin.

139. (withdrawn, currently amended) The method of claim 95, further comprising ~~the step of~~:

applying said vasoconstrictor, said penetration enhancer, and said *ketoprofen* to the patient's skin.

140. (withdrawn, currently amended) The method of claim 99, further comprising ~~the step of~~:

applying said vasoconstrictor, said penetration enhancer, and said long-acting non-steroidal anti-inflammatory agent to the patient's skin.

141. (withdrawn, currently amended) The method of claim 100, further comprising ~~the step of~~:

applying said vasoconstrictor, said penetration enhancer, and said *piroxicam* to the patient's skin.

142. (withdrawn, currently amended) The method of claim 110, further comprising ~~the step of~~:

applying said vasoconstrictor, said penetration enhancer, said local anesthetic, said quick-onset, short-acting non-steroidal anti-inflammatory agent, and said long-acting non-

steroidal anti-inflammatory agent to the patient's skin.

143. (withdrawn, currently amended) The method of claim 111, further comprising ~~the step of~~:

applying said vasoconstrictor, said penetration enhancer, said *bupivacaine*, said *ketoprofen*, and said *piroxicam* to the patient's skin.

144. (withdrawn, currently amended) The method of claim 114, further comprising ~~the step of~~:

applying said vasoconstrictor, said penetration enhancer, and said antiviral agent to the patient's skin.

145. (withdrawn, currently amended) The method of claim 115, further comprising ~~the step of~~:

applying said vasoconstrictor, said penetration enhancer, and said *2-deoxy-d-glucose* to the patient's skin.

146. (withdrawn, currently amended) The method of claim 119, further comprising ~~the step of~~:

applying said vasoconstrictor, said penetration enhancer, therapeutic pain-relieving agent, and said antiviral agent to the patient's skin.

147. (withdrawn, currently amended) The method of claim 120, further comprising ~~the step of~~:

applying said vasoconstrictor, said penetration enhancer, therapeutic pain-relieving agent, and said *2-deoxy-d-glucose* to the patient's skin.

148. (withdrawn, currently amended) The method of claim 124, further comprising ~~the step of~~:

applying said *phenylephrine*, said penetration enhancing agent selected from the penetration-enhancing agent group consisting of *dimethylsulfoxide* and *lecithin*, said *bupivacaine*, said *ketoprofen*, and said *piroxicam* to the patient's skin.

149. (withdrawn, currently amended) The method of claim 127, further comprising ~~the step of~~:

applying said vasoconstrictor, said penetration enhancer, said local anesthetic, said quick-onset, short-acting non-steroidal anti-inflammatory agent, said long-acting non-steroidal anti-inflammatory agent, and said antiviral agent to the patient's skin.

150. (withdrawn, currently amended) The method of claim 128, further comprising ~~the step of~~:

applying said *phenylephrine*, said penetration enhancing agent selected from the penetration-enhancing agent group consisting of *dimethylsulfoxide* and *lecithin*, said *bupivacaine*, said *ketoprofen*, said *piroxicam*;, and said *2-deoxy-d-glucose* to the patient's skin.